 |
|
|
|
|
|
 Title: |
US6083510:
High molecular weight extracts of Convolvulus arvensis field (field bindweed)
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Meng, Xiaolong; Wichita, KS
Riordan, Hugh D.; Wichita, KS
Riordan, Neil H.; Wichita, KS
|
| Assignee: |
The Center for the Improvement of Human Functioning, Int'l., Inc., Wichita, KS
other patents from THE CENTER FOR THE IMPROVEMENT OF HUMAN FUNCTIONING INT'L, INC. (731044) (approx. 7)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
2000-07-04
/ 1999-02-16
|
| Application Number: |
US1999000249874
|
| IPC Code: |
Advanced:
A61K 36/00;
A61K 36/18;
A61K 36/39;
A61P 35/00;
A61P 37/04;
A61P 43/00;
Core:
A61K 36/185;
A61P 37/00;
more...
IPC-7:
A01N 65/00;
|
| ECLA Code: |
A61K36/39;
|
| U.S. Class: |
Current:
424/725;
Original:
424/195.1;
|
| Field of Search: |
424/195.1
|
| Priority Number: |
| 1999-02-16 |
US1999000249874 |
|
| Abstract: |
A purified bindweed extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed extract is prepared by removing toxic low molecular weight components of Convolvulus arvensis.
|
| Attorney, Agent or Firm: |
Knobbe, Martens, Olson & Bear, LLP ;
|
| Primary / Asst. Examiners: |
Lilling, Herbert J.;
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
| Designated Country: |
AE AL AM AP AT AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EA EE EP ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
|
| Family: |
Show 20 known family members
|
First Claim:
Show all 24 claims |
What is claimed is:
1. A pharmaceutical composition for treating cancer, inhibiting the growth of new blood vessels, and/or enhancing immune function in a mammal, said composition comprising: an effective amount of an aqueous extract of Convolvulus arvensis prepared by a process comprising:
- homogenizing Convolvulus arvensis plant parts;
- preparing said aqueous extract from said plant parts; and
- substantially removing components from said extract of molecular weight less than about 500 Daltons, said pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 2 U.S. patent(s) that reference this one
|
Nominate this for the Gallery...
